PPAR: A therapeutic target in parkinson's disease

Journal of Neurochemistry

Volumn 106, Issue 2, 2008, Pages 506-518

  Chaturvedi, Rajnish K ^a   Beal, M F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Mitochondrial dysfunction; Neuroprotection; Oxidative stress; Parkinson's disease; Peroxisome proliferator Activated receptor; Ppar gamma coactivator 1alpha

Indexed keywords

4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ACETYLSALICYLIC ACID; BEZAFIBRATE; CELECOXIB; DICLOFENAC; FENOFIBRATE; FENOPROFEN; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROTEOME; ROSIGLITAZONE; SALICYLATE SODIUM; ANTIPARKINSON AGENT;

ALZHEIMER DISEASE; AMNESIA; APOPTOSIS; CELL DEATH; CELL FUNCTION; CELL SURVIVAL; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GENE CONTROL; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LEARNING DISORDER; MITOCHONDRION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; ANIMAL; DRUG POTENTIATION; METABOLISM;

ANIMALS; ANTIPARKINSON AGENTS; HUMANS; PARKINSON DISEASE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 51649110738     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05388.x     Document Type: Review

References (143)

1. Abdelrahman M., Sivarajah A. and Thiemermann C. (2005) Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc. Res. 65, 772-781.
2. Anglade P., Vyas S., Javoy-Agid F., Herrero M. T., Michel P. P., Marquez J., Mouatt-Prigent A., Ruberg M., Hirsch E. C. and Agid Y. (1997) Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 12, 25-31.
3. Beal M. F. (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 44, S110-S114.
4. Beal M. F. (2002) Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 32, 797-803.
5. Beal M. F. (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991, 120-131.
6. Beal M. F. (2005) Mitochondria take center stage in aging and neuro- degeneration. Ann. Neurol 58, 495-505.
7. Bender A., Krishnan K. J., Morris C. M. et al. (2006) High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38, 515-517.
8. Berger J. and Moller D. E. (2002) The mechanisms of action of PPARs. Annu. Rev. Med. 53, 409-435.
9. Berger J. P., Akiyama T. E. and Meinke P. T. (2005) PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244-251.
10. Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 1301-1306.
11. Bindoff L. A., Birch-Machin M., Cartlidge N. E., Parker Jr W. D. and Turnbull D. M. (1989) Mitochondrial function in Parkinson's disease. Lancet 2, 49.
12. Bishop-Bailey D. (2000) Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol. 129, 823-834.
13. Bogacka I., Xie H., Bray G. A. and Smith S. R. (2005) Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54, 1392-1399.
14. Bordet R., Ouk T., Petrault O. et al. (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 34, 1341-1346.
15. Breidert T., Callebert J., Heneka M. T., Landreth G., Launay J. M. and Hirsch E. C. (2002) Protective action of the peroxisome pro- liferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624.
16. Buchan K. W. and Hassall D. G. (2000) PPAR agonists as direct modulators of the vessel wall in cardiovascular disease. Med. Res. Rev. 20, 350-366.
17. Camacho I. E., Serneels L., Spittaels K., Merchiers P., Dominguez D. and De Strooper B. (2004) Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24, 10908-10917.
18. Cao Z., Ye P., Long C., Chen K., Li X. and Wang H. (2007) Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats. Pharmacology 79, 184-192.
19. Casper D., Yaparpalvi U., Rempel N. and Werner P. (2000) Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci. Lett. 289, 201-204. Castrillo A. and Tontonoz P. (2004) Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20, 455-180.
20. Chen H., Zhang S. M., Hernan M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E. and Ascherio A. (2003) Non-steroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059-1064.
21. Chen H., Jacobs E., Schwarzschild M. A., McCullough M. L., Calle E. E., Thun M. J. and Ascherio A. (2005) Nonsteroidal antiin- flammatory drug use and the risk for Parkinson's disease. Ann. Neurol 58, 963-967.
22. Chung J. H., Seo A. Y., Chung S. W., Kim M. K., Leeuwenburgh C., Yu B. P. and Chung H. Y. (2008) Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res. Rev. (In Press). Colca J. R., McDonald W. G., Waldon D. J., Leone J. W., Lull J. M., Bannow C. A., Lund E. T. and Mathews W. R. (2004) Identification of a novel mitochondrial protein ('mitoNEET') cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol Endocrinol. Metab. 286, E252-E260.
23. Cui L., Jeong H., Borovecki F., Parkhurst C. N., Tanese N. and Krainc D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegen- eration. Cell 127, 59-69.
24. Culman J., Zhao Y., Gohlke P. and Herdegen T. (2007) PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol. Sci. 28, 244-249.
25. Das S. K. and Chakrabarti R. (2006) Role of PPAR in cardiovascular iseases. Recent Patents Cardiovasc. Drug Discov. 1, 193-209.
26. Dawson T. M. and Dawson V. L. (2002) Neuroprotective and neuro-restorative strategies for Parkinson's disease. Nat. Neurosci. 5(Suppl), 1058-1061.
27. Dawson T. M. and Dawson V. L. (2003) Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111, 145-151.
28. Dehmer T., Heneka M. T., Sastre M., Dichgans J. and Schulz J. B. (2004) Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J. Neurochem. 88, 494-501.
29. Dello Russo C., Gavrilyuk V., Weinberg G., Almeida A., Bolanos J. P., Palmer J., Pelligrino D., Galea E. and Feinstein D. L. (2003) Peroxisome proliferator-activated receptor gamma thiazolidine- dione agonists increase glucose metabolism in astrocytes. J. Biol Chem. 278, 5828-5836.
30. Desvergne B. and Wahli W. (1999) Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688.
31. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P. and Marsden C. D. (1989a) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52, 1830-1836.
32. Dexter D. T., Carter C. J., Wells F. R., Javoy-Agid F., Agid Y., Lees A., Jenner P. and Marsden C. D. (1989b) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
33. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G. and Di Giovanni G. (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205, 295-312.
34. Fediuc S., Pimenta A. S., Gaidhu M. P. and Ceddia R. B. (2008) Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells. J. Cell. Physiol. 2l5, 392-400.
35. Feinstein D. L., Spagnolo A., Akar C., Weinberg G., Murphy P., Gav- rilyuk V. and Dello Russo C. (2005) Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70, 177-188.
36. Floor E. and Wetzel M. G. (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dini- trophenylhydrazine assay. J. Neurochem. 70, 268-275.
37. Fuenzalida K., Quintanilla R., Ramos P., Piderit D., Fuentealba R. A., Martinez G., Inestrosa N. C. and Bronfman M. (2007) Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti- apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282, 37006-37015.
38. Fukae J., Takanashi M., Kubo S., Nishioka K., Nakabeppu Y., Mori H., Mizuno Y. and Hattori N. (2005) Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders. Acta Neuropathol. 109, 256-262.
39. Ghosh S., Patel N., Rahn D., McAllister J., Sadeghi S., Horwitz G., Berry D., Wang K. X. and Swerdlow R. H. (2007) The thiazoli- dinedione pioglitazone alters mitochondrial function in human neuron-like cells. Mol. Pharmacol. 7l, 1695-1702.
40. Gofflot F., Chartoire N., Vasseur L., Heikkinen S., Dembele D., Le Merrer J. and Auwerx J. (2007) Systematic gene expression mapping clusters nuclear receptors according to their function in the brain. Cell 131, 405-418.
41. Grommes C., Landreth G. E. and Heneka M. T. (2004) Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 5, 4 19-429.
42. Gross B. and Staels B. (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab. 21, 687-710.
43. Gu M., Cooper J. M., Taanman J. W. and Schapira A. H. (1998) Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44, 177-186.
44. Gu G., Reyes P. E., Golden G. T., Woltjer R. L., Hulette C., Montine T. J. and Zhang J. (2002) Mitochondrial DNA deletions/rearrangements in parkinson disease and related neurodegenerative disorders. J. Neuropathol. Exp. Neurol. 61, 634-639.
45. Haas R. H., Nasirian F., Nakano K., Ward D., Pay M., Hill R. and Shults C. W. (1995) Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37, 714-722.
46. Han S. and Roman J. (2007) Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs 18, 237-244.
47. Han K. L., Choi J. S., Lee J. Y., Song J., Joe M. K., Jung M. H. and Hwang J. K. (2008) Therapeutic potential of peroxisome pro- liferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes. Diabetes 57, 737-745.
48. Hartmann A., Hunot S., Michel P. P. et al. (2000) Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl Acad. Sci. USA 97, 2875-2880.
49. Hartmann A., Mouatt-Prigent A., Vila M., Abbas N., Perier C., Faucheux B. A., Vyas S. and Hirsch E. C. (2002) Increased expression and redistribution of the antiapoptotic molecule Bcl-xL in Parkinson's disease. Neurobiol. Dis. 10, 28-32.
50. Heneka M. T. and Landreth G. E. (2007) PPARs in the brain. Biochim. Biophys. Acta 1771, 1031-1045.
51. Heneka M. T., Landreth G. E. and Feinstein D. L. (2001) Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease. Ann. Neurol. 49, 276.
52. Heneka M. T., Sastre M., Dumitrescu-Ozimek L., Hanke A., Dewachter I., Kuiperi C., O'Banion K., Klockgether T., Van Leuven F. and Landreth G. E. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
53. Heneka M. T., Landreth G. E. and Hull M. (2007) Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat. Clin. Pract. Neurol. 3, 496-504.
54. Hollingshead H. E., Borland M. G., Billin A. N., Willson T. M., Gonzalez F. J. and Peters J. M. (2008) Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carci- nogenesis through independent signaling mechanisms. Carcino- genesis 29, 169-176.
55. Hunot S., Brugg B., Ricard D., Michel P. P., Muriel M. P., Ruberg M., Faucheux B. A., Agid Y. and Hirsch E. C. (1997) Nuclear trans- location of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl Acad. Sci. USA 94, 7531-7536.
56. Hunter R. L., Dragicevic N., Seifert K., Choi D. Y., Liu M., Kim H. C., Cass W. A., Sullivan P. G. and Bing G. (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegen- eration in the nigrostriatal system. J. Neurochem. 100, 1375-1386.
57. Hunter R. L., Choi D. Y., Ross S. A. and Bing G. (2008) Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci. Lett. 432, 198-201.
58. Iwashita A., Muramatsu Y., Yamazaki T., Muramoto M., Kita Y., Yamazaki S., Mihara K., Moriguchi A. and Matsuoka N. (2007) Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo. J. Pharmacol. Exp. Ther. 320, 1087-1096.
59. Jenner P. (1998) Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13(Suppl 1), 24-34.
60. Jiang C., Ting A. T. and Seed B. (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
61. Jiang Q., Heneka M. and Landreth G. E. (2008) The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs 22, 1-14.
62. Jung T. W., Lee J. Y., Shim W. S., Kang E. S., Kim S. K., Ahn C. W., Lee H. C. and Cha B. S. (2006) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem. Biophys. Res. Commun. 340, 221-227.
63. Jung T. W., Lee J. Y., Shim W. S., Kang E. S., Kim S. K., Ahn C. W., Lee H. C. and Cha B. S. (2007) Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production. J.Neurol. Sci. 253, 53-60.
64. Kamei Y., Xu L., Heinzel T. et al. (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85, 403-U4.
65. Kapadia R., Yi J. H. and Vemuganti R. (2008) Mechanisms of anti- inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 13, 1813-1826.
66. Kiaei M., Kipiani K., Chen J., Calingasan N. Y. and Beal M. F. (2005) Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis. Exp. Neurol. 191, 331-336.
67. Kiyota Y., Kondo T., Maeshiba Y., Hashimoto A., Yamashita K., Yoshi- mura Y., Motohashi M. and Tanayama S. (1997) Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 47, 22-28.
68. Kraytsberg Y., Kudryavtseva E., McKee A. C., Geula C., Kowall N. W. and Khrapko K. (2006) Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38, 518-520.
69. Kreisler A., Gele P., Wiart J. F., Lhermitte M., Destee A. and Bordet R. (2007) Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res. 1135, 77-84.
70. Kurkowska-Jastrzebska I., Babiuch M., Joniec I., Przybylkowski A., Czlonkowski A. and Czlonkowska A. (2002) Indomethacin protects against neurodegeneration caused by MPTP intoxication in mice. Int. Immunopharmacol. 2, 1213-1218.
71. Langston J. W., Ballard P., Tetrud J. W. and Irwin I. (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980.
72. Lee J. and Reding M. (2007) Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem. Res. 32, 635-638.
73. Lehmann J. M., Lenhard J. M., Oliver B. B., Ringold G. M. and Kliewer S. A. (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti- inflammatory drugs. J. Biol. Chem. 272, 3406-3410.
74. Letavernier E., Perez J., Joye E., Bellocq A., Fouqueray B., Haymann J. P., Heudes D., Wahli W., Desvergne B. and Baud L. (2005) Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J. Am. Soc. Nephrol. 16, 2395-2402.
75. Liang C. L., Wang T. T., Luby-Phelps K. and German D. C. (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp. Neurol. 203, 370-380. Lin M. T. and Beal M. F. (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795.
76. Luo Y., Yin W., Signore A. P., Zhang F., Hong Z., Wang S., Graham S. H. and Chen J. (2006) Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor- gamma agonist rosiglitazone. J. Neurochem. 97, 435-448.
77. Luoma P. T., Eerola J., Ahola S., Hakonen A. H., Hellstrom O., Kivisto K. T., Tienari P. J. and Suomalainen A. (2007) Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 69, 1152-1159.
78. McGeer P. L., Itagaki S., Boyes B. E. and McGeer E. G. (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291.
79. McGill J. K. and Beal M. F. (2006) PGC-1alpha, a new therapeutic target in Huntington's disease? Cell 127, 465-468. McNaught K. S., Olanow C. W., Halliwell B., Isacson O. and Jenner P. (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2, 589-594.
80. McNaught K. S., Belizaire R., Jenner P., Olanow C. W. and Isacson O. (2002) Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci. Lett. 326, 155-158.
81. McNaught K. S., Belizaire R., Isacson O., Jenner P. and Olanow C. W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38-46.
82. McTigue D. M., Tripathi R., Wei P. and Lash A. T. (2007) The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp. Neurol. 205, 396-406.
83. Miwa H., Kubo T., Suzuki A., Nishi K. and Kondo T. (2005) Retrograde dopaminergic neuron degeneration following intrastriatal protea- some inhibition. Neurosci. Lett. 380, 93-98.
84. Mogi M., Harada M., Kondo T., Mizuno Y., Narabayashi H., Riederer P. and Nagatsu T. (1996) Bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 215, 137-139.
85. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H. and Nagatsu T. (2000) Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J. Neural Transm. 107, 335-341.
86. Mogi M., Kondo T., Mizuno Y. and Nagatsu T. (2007) p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the par- kinsonian brain. Neurosci. Lett. 414, 94-97.
87. Moon Y. S., Chun P. and Chung S. (2007) Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia. Drugs Today (Barc) 43, 35-45.
88. Nagatsu T., Mogi M., Ichinose H. and Togari A. (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm. Suppl. 60, 277-290.
89. van Neerven S. and Mey J. (2007) RAR/RXR and PPAR/RXR signaling in spinal cord injury. PPAR Res. 2007, 29275.
90. Niino M. (2007) Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis. Mini Rev. Med. Chem. 7, 1129-1135.
91. Nolte R. T., Wisely G. B., Westin S., Cobb J. E., Lambert M. H., Kurokawa R., Rosenfeld M. G., Willson T. M., Glass C. K. and Milburn M. V. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395, 137-143.
92. Oberkofler H., Esterbauer H., Linnemayr V., Strosberg A. D., Krempler F. and Patsch W. (2002) Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. J. Biol. Chem. 277, 16750-16757.
93. Paddock M. L., Wiley S. E., Axelrod H. L. et al. (2007) MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc. Natl Acad. Sci. USA 104, 14342-14347.
94. Park S. W., Yi J. H., Miranpuri G., Satriotomo I., Bowen K., Resnick D. K. and Vemuganti R. (2007) Thiazolidinedione class of per- oxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J. Pharmacol. Exp. Ther. 320, 1002-1012.
95. Pascual G. and Glass C. K. (2006) Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol. Metab. 17, 321-327.
96. Pedersen W. A. and Flynn E. R. (2004) Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease. Neurobiol. Dis. 17, 500-506.
97. Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S. and Haynatzki G. R. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp. Neurol. 199, 265-273.
98. Puigserver P., Wu Z., Park C. W., Graves R., Wright M. and Spiegelman B. M. (1998) A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829-839.
99. Qi C., Zhu Y. and Reddy J. K. (2000) Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem. Biophys. 32, 187-204.
100. Quinn C. E., Hamilton P. K., Lockhart C. J. and McVeigh G. E. (2008a) Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br. J. Pharmacol. 153, 636-645.
101. Quinn L. P., Crook B., Hows M. E., Vidgeon-Hart M., Chapman H., Upton N., Medhurst A. D. and Virley D. J.(2008b) The PPAR- gamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition ofmonoamine oxidase B. Br. J. Pharmacol. (In Press).
102. Reddy J. K. and Hashimoto T. (2001) Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 21, 193-230.
103. Reddy J. K. and Rao M. S. (2006) Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G852-G858.
104. Ricote M., Li A. C., Willson T. M., Kelly C. J. and Glass C. K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
105. Risner M. E., Saunders A. M., Altman J. F., Ormandy G. C., Craft S., Foley I. M., Zvartau-Hind M. E., Hosford D. A. and Roses A. D. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254.
106. Sastre M., Dewachter I., Rossner S. et al. (2006) Nonsteroidal anti- inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl Acad. Sci. USA 103, 443-448.
107. Schapira A. H. (2007) Mitochondrial dysfunction in Parkinson's disease. Cell Death Differ. 14, 1261-1266.
108. Schapira A. H. (2008) Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 7, 97-109.
109. Schapira A. H., Cooper J. M., Dexter D., Clark J. B., Jenner P. and Marsden C. D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54, 823-827.
110. Schutz B., Reimann J., Dumitrescu-Ozimek L., Kappes-Horn K., Landreth G. E., Schurmann B., Zimmer A. and Heneka M. T. (2005) The oral antidiabetic pioglitazone protects from neurode-generation and amyotrophic lateral sclerosis-like symptoms in su- peroxide dismutase-G93A transgenic mice. J. Neurosci. 25, 7805-7812.
111. Sian J., Dexter D. T., Lees A. J., Daniel S., Jenner P. and Marsden C. D. (1994a) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356-361.
112. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P. and Marsden C. D. (1994b) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348-355.
113. Silva J. E. and Rabelo R. (1997) Regulation of the uncoupling protein gene expression. Eur. J. Endocrinol. 136, 251-264.
114. Simon D. K., Lin M. T., Zheng L., Liu G. J., Ahn C. H., Kim L. M., Mauck W. M., Twu F., Beal M. F. and Johns D. R. (2004) Somatic
115. mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging 25, 71-81.
116. St-Pierre J., Drori S., Uldry M. et al. (2006) Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127, 397-408.
117. Straus D. S. and Glass C. K. (2001) Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21, 185-210.
118. Straus D. S. and Glass C. K. (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28, 551-558.
119. Strum J. C., Shehee R., Virley D., Richardson J., Mattie M., Selley P., Ghosh S., Nock C., Saunders A. and Roses A. (2007) Rosiglitazone induces mitochondrial biogenesis in mouse brain. J. Alzhei- mers Dis. 11, 45-51.
120. Sundararajan S., Jiang Q., Heneka M. and Landreth G. (2006) PPAR-gamma as a therapeutic target in central nervous system diseases. Neurochem. Int. 49, 136-144.
121. Tansey M. G., McCoy M. K. and Frank-Cannon T. C. (2007) Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp. Neurol. 208, 1-25.
122. Testa C. M., Sherer T. B. and Greenamyre J. T. (2005) Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 134, 109-118.
123. Thomas B. and Beal M. F. (2007) Parkinson's disease. Hum. Mol. Genet. 16 Spec No. 2, R183-R194.
124. Tureyen K., Kapadia R., Bowen K. K., Satriotomo I., Liang J., Feinstein D. L. and Vemuganti R. (2007) Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 101, 41-56.
125. Turturro F., Oliver III R., Friday E., Nissim I. and Welbourne T. (2007) Troglitazone and pioglitazone interactions via PPAR-gamma-in- dependent and -dependent pathways in regulating physiological responses in renal tubule-derived cell lines. Am. J. Physiol. Cell Physiol. 292, C1137-C1146.
126. Ulivieri C. and Baldari C. T. (2007) The potential of peroxisome pro- liferator-activated receptor gamma (PPARgamma) ligands in the treatment of hematological malignancies. Mini Rev. Med. Chem. 7, 877-887.
127. Vega R. B., Huss J. M. and Kelly D. P. (2000) The coactivator PGC- 1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol. Cell. Biol. 20, 1868-1876.
128. Villarroya F., Iglesias R. and Giralt M. (2007) PPARs in the control of uncoupling proteins gene expression. PPAR Res. 2007, 74364.
129. Wan Y., Chong L. W. and Evans R. M. (2007) PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13, 1496-1503.
130. Wang X. M. and Chen D. F. (2007) Effects of rosiglitazone on Kruppul- like factor 6(KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 15, 649-653.
131. Wang Y. L., Frauwirth K. A., Rangwala S. M., Lazar M. A. and Thompson C. B. (2002) Thiazolidinedione activation of peroxisome pro- liferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J. Biol. Chem. 277, 31781-31788.
132. Watson G. S., Cholerton B. A., Reger M. A. et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am. J. Geriatr. Psychiatry 13, 950-958.
133. Weggen S., Rogers M. and Eriksen J. (2007) NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol. Sci. 28, 536-543.
134. Weydt P., Pineda V. V., Torrence A. E. et al. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362.
135. Wiley S. E., Murphy A. N., Ross S. A., van der Geer P. and Dixon J. E. (2007) MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc. Natl Acad. Sci. USA 104, 5318-5323.
136. Willson T. M., Brown P. J., Sternbach D. D. and Henke B. R. (2000) The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43, 527-550.
137. Woods J. W., Tanen M., Figueroa D. J., Biswas C., Zycband E., Moller D. E., Austin C. P. and Berger J. P. (2003) Localization of PPARdelta in murine central nervous system: expression in oli- godendrocytes and neurons. Brain Res. 975, 10-21.
138. Xin B., Yokoyama Y., Shigeto T., Futagami M. and Mizunuma H. (2007) Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer 110, 791-800.
139. Xing B., Liu M. and Bing G. (2007) Neuroprotection with pioglita- zone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF-kappaB and JNK activation and suppression of COX-2 activity. J. Neuroimmunol. 192, 89-98.
140. Xing B., Xin T., Hunter R. L. and Bing G. (2008) Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt. J. Neu- roinflammation 5,4.
141. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E. R. and Mizuno Y. (1996) Immunohistochemical detection of 4-hydro- xynonenal protein adducts in Parkinson disease. Proc. Natl Acad. Sci. USA 93, 2696-2701.
142. Zhang W., Wang T., Pei Z. et al. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19, 533-542.
143. Ziouzenkova O. and Plutzky J. (2008) Retinoid metabolism and nuclear receptor responses: new insights into coordinated regulation of the PPAR-RXR complex. FEBS Lett. 582, 32-38.